Literature DB >> 35107653

Erosive Hand OsteoArthritis (EHOA): analysis of consecutive patients presenting with EHOA in a hospital-based rheumatology practice and its implications for an upcoming interventional study.

Tanja Giesen1, Sebastian Sanduleanu1, Tim L Th A Jansen2.   

Abstract

INTRODUCTION: Erosive Hand OsteoArthritis (EHOA) is a common rheumatological problem. We aim to determine characteristics of EHOA patients: comorbidities, radiographic erosivity and pain experienced after being diagnosed, in order to find which of these are potentially relevant in upcoming interventional trials.
METHOD: Retrospective analysis of EHOA patients within the electronic database in one centre, with a telephone interview on pain as experienced even exceeding 12 months after being diagnosed.
RESULTS: Eighty-four non-academic EHOA patients were found: 89% females (median age 69 years), 11% males (similar age distribution). Kellgren-Lawrence (KL) erosivity scores in both sexes were comparable; DIPs scored higher than PIP's. Comorbid conditions were crystal-induced arthritis, rheumatoid arthritis (RA) and psoriatic arthritis (PsA) in 8%, 5% and 1%, respectively; seropositivity for rheumatoid factor and anti-citrullinated protein antibodies in 8% and 1% respectively. Pain worst experienced often exceeded a visual analogue score of 5.0, but was unrelated to the total KL score. Some pain reduction was reached with non-steroidals (perorally/transcutaneously) as deduced from continued use in 1 in 3.
CONCLUSIONS: In many EHOA patients, there is an unmet need regarding the treatment of pain, which per se was not directly correlated with erosivity score. Future studies may be designed considering the aforementioned characteristics, acting on the inflammatory process resulting in PIP/DIP erosions, with the exclusion of RA and PsA in order to get a clean study on EHOA. Several studies with monoclonal antibodies have been performed but demonstrated ineffectivity on the outcome of pain. Hope glooms with the arrival of innovative small molecules that may reach EHOA target cells. Key Points • Erosive handOA is a common problem in non-academic rheumatology; it is often associated with significant pain in both sexes exceeding a VASpain of 5.0 even years after being diagnosed; 1 in 3 found some relief in non-steroidals perorally/transcutaneously. • Future studies will have to focus on (episodic) inflammatory hand OA resulting in proven erosivity (EHOA) located in PIP plus DIP joints and may have to exclude comorbid active crystal-induced arthritis as well as rheumatoid/psoriatic arthritis and possibly even RF/ACPA seropositivity in order to get a clean study on EHOA. • As several big monoclonals have failed in EHOA, we may have to search for promising new drugs within the group of small molecules. These will have to show a significant pain-reducing effect and preferably also a disease-modifying osteoarthritis drug (DMOAD) effect.
© 2022. International League of Associations for Rheumatology (ILAR).

Entities:  

Keywords:  Cross-sectional population study; Erosive hand osteoarthritis; Interleukin 1 inhibitor; NLRP3 inhibitor; Pharmacotherapy

Mesh:

Substances:

Year:  2022        PMID: 35107653     DOI: 10.1007/s10067-022-06073-7

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  13 in total

1.  Radiological assessment of osteo-arthrosis.

Authors:  J H KELLGREN; J S LAWRENCE
Journal:  Ann Rheum Dis       Date:  1957-12       Impact factor: 19.103

2.  The association between erosive hand osteoarthritis and subchondral bone attrition of the knee: the Framingham Osteoarthritis Study.

Authors:  Ida Kristin Haugen; David T Felson; Martin Englund; Ke Wang; Piran Aliabadi; Ali Guermazi; Frank W Roemer; Tuhina Neogi
Journal:  Ann Rheum Dis       Date:  2012-06-23       Impact factor: 19.103

3.  Results of a 6-week treatment with 10 mg prednisolone in patients with hand osteoarthritis (HOPE): a double-blind, randomised, placebo-controlled trial.

Authors:  Féline P B Kroon; Marion C Kortekaas; Annelies Boonen; Stefan Böhringer; Monique Reijnierse; Frits R Rosendaal; Naghmeh Riyazi; Mirian Starmans; Franktien Turkstra; Jende van Zeben; Cornelia F Allaart; Margreet Kloppenburg
Journal:  Lancet       Date:  2019-11-11       Impact factor: 79.321

4.  Validity and factor structure of the AUSCAN Osteoarthritis Hand Index in a community-based sample.

Authors:  K D Allen; R F DeVellis; J B Renner; V B Kraus; J M Jordan
Journal:  Osteoarthritis Cartilage       Date:  2007-02-27       Impact factor: 6.576

5.  Efficacy of tocilizumab in patients with hand osteoarthritis: double blind, randomised, placebo-controlled, multicentre trial.

Authors:  Augustin Latourte; Jérémie Sellam; Pascal Richette; Daniel Wendling; Muriel Piperno; Philippe Goupille; Yves-Marie Pers; Florent Eymard; Sébastien Ottaviani; Paul Ornetti; René-Marc Flipo; Bruno Fautrel; Olivier Peyr; Jean Pierre Bertola; Eric Vicaut; Xavier Chevalier
Journal:  Ann Rheum Dis       Date:  2020-10-14       Impact factor: 19.103

6.  Etanercept in patients with inflammatory hand osteoarthritis (EHOA): a multicentre, randomised, double-blind, placebo-controlled trial.

Authors:  Margreet Kloppenburg; Roberta Ramonda; Klaus Bobacz; Wing-Yee Kwok; Dirk Elewaut; Tom W J Huizinga; Féline P B Kroon; Leonardo Punzi; Josef S Smolen; Bert Vander Cruyssen; Ron Wolterbeek; Gust Verbruggen; Ruth Wittoek
Journal:  Ann Rheum Dis       Date:  2018-10-03       Impact factor: 19.103

7.  A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the knee.

Authors:  Stanley B Cohen; Susanna Proudman; Alan J Kivitz; Francis X Burch; John P Donohue; Deborah Burstein; Yu-Nien Sun; Christopher Banfield; Michael S Vincent; Liyun Ni; Debra J Zack
Journal:  Arthritis Res Ther       Date:  2011-07-29       Impact factor: 5.156

8.  Adalimumab in patients with hand osteoarthritis refractory to analgesics and NSAIDs: a randomised, multicentre, double-blind, placebo-controlled trial.

Authors:  X Chevalier; P Ravaud; E Maheu; G Baron; A Rialland; P Vergnaud; C Roux; Y Maugars; D Mulleman; C Lukas; D Wendling; P Lafforgue; D Loeuille; V Foltz; P Richette
Journal:  Ann Rheum Dis       Date:  2014-05-09       Impact factor: 19.103

9.  Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial.

Authors:  Viola Klück; Tim L Th A Jansen; Matthijs Janssen; Antoaneta Comarniceanu; Monique Efdé; Isak W Tengesdal; Kiki Schraa; Maartje C P Cleophas; Curtis L Scribner; Damaris B Skouras; Carlo Marchetti; Charles A Dinarello; Leo A B Joosten
Journal:  Lancet Rheumatol       Date:  2020-04-08

Review 10.  Hand Erosive Osteoarthritis and Distal Interphalangeal Involvement in Psoriatic Arthritis: The Place of Conservative Therapy.

Authors:  Elena Poletto; Ilaria Tinazzi; Antonio Marchetta; Nicola Smania; Elena Rossato
Journal:  J Clin Med       Date:  2021-06-15       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.